Pour rechercher une publication scientifique, insérez vos mots-clés en anglais.

Epidemiological characteristics and real-world treatment outcomes of hepatitis C among HIV/HCV co-infected patients in Myanmar: A prospective cohort study.


BACKGROUND AND AIMS: In Myanmar, public sector treatment programs for hepatitis C virus (HCV) infection were nonexistent until June 2017.

Swe TM Johnson DC Mar HT Thit P Homan T Chu CM Mon PE Thwe TT Soe KP Ei WLSS Tun NL Lwin KZ Karakozian H Aung KS Nguyen A Ciglenecki I Tamayo N Loarec A
Health science reports 2023 Feb ; 6(2); . doi: 10.1002/hsr2.1119. Epub 2023 02 17
HIV Myanmar epidemiology hepatitis C sustained virologic response

Prognostic value of different anthropometric indices over different measurement intervals to predict mortality in 6-59-month-old children.


OBJECTIVE: To compare the prognostic value of mid-upper arm circumference (MUAC), weight-for-height z-score (WHZ) and weight-for-age z-score (WAZ) for predicting death over periods of one, three and six months follow-up in children.

Briend A Myatt M Berkley JA Black RE Boyd E Garenne M Lelijveld N Isanaka S McDonald CM Mwangwome M O'Brien KS Schwinger C Stobaugh H Taneja S West KP Khara T
Public health nutrition 2023 Feb 01; . doi: 10.1017/S1368980023000149. Epub 2023 02 01
Anthropometry Mid-upper arm circumference Mortality Stunting Underweight Wasting

Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis.


BACKGROUND: Evidence on the comparative performance of purified protein derivative tuberculin skin tests (TST) and interferon-gamma release assays (IGRA) for predicting incident active tuberculosis (TB) remains conflicting.

Hamada Y Gupta RK Quartagno M Izzard A Acuna-Villaorduna C Altet N Diel R Dominguez J Floyd S Gupta A Huerga H Jones-López EC Kinikar A Lange C van Leth F Liu Q Lu W Lu P Rueda IL Martinez L Mbandi SK Muñoz L Padilla ES Paradkar M Scriba T Sester M Shanaube K Sharma SK Sloot R Sotgiu G Thiruvengadam K Vashishtha R Abubakar I Rangaka MX
EClinicalMedicine 2023 Feb ; 56; . doi: 10.1016/j.eclinm.2022.101815. Epub 2023 01 05
IGRA LTBI Prevention Prophylaxis Tuberculin skin test

A global core outcome measurement set for snakebite clinical trials.


Snakebite clinical trials have often used heterogeneous outcome measures and there is an urgent need for standardisation.

Abouyannis M Esmail H Hamaluba M Ngama M Mwangudzah H Mumba N Yeri BK Mwalukore S Alphan HJ Aggarwal D Alcoba G Cammack N Chippaux JP Coldiron ME Gutiérrez JM Habib AG Harrison RA Isbister GK Lavonas EJ Martins D Ribeiro I Watson JA Williams DJ Casewell NR Walker SA Lalloo DG
The Lancet. Global health 2023 Feb ; 11(2); . doi: 10.1016/S2214-109X(22)00479-X. Epub 2023 01 25

Breakthrough treatments for Ebola virus disease, but no access-what went wrong, and how can we do better?


Three years since proving effective for Ebola virus disease in a clinical trial, two breakthrough treatments are registered and stockpiled in the USA but still not registered and generally available in the countries most affected by this deadly infecti

Torreele E Boum Y Adjaho I Alé FGB Issoufou SH Harczi G Okonta C Olliaro P
The Lancet. Infectious diseases 2023 Jan 19; . doi: 10.1016/S1473-3099(22)00810-6. Epub 2023 01 19

Novel FujiLAM assay to detect tuberculosis in HIV-positive ambulatory patients in four African countries: a diagnostic accuracy study.


BACKGROUND: Development of rapid biomarker-based tests that can diagnose tuberculosis using non-sputum samples is a priority for tuberculosis control.

Huerga H Bastard M Lubega AV Akinyi M Antabak NT Ohler L Muyindike W Taremwa IM Stewart R Bossard C Nkosi N Ndlovu Z Hewison C Stavia T Okomo G Ogoro JO Ngozo J Mbatha M Aleny C Wanjala S Musoke M Atwine D Ascorra A Ardizzoni E Casenghi M Ferlazzo G Nakiyingi L Gupta-Wright A Bonnet M
The Lancet. Global health 2023 Jan ; 11(1); . doi: 10.1016/S2214-109X(22)00463-6. Epub 2022 12 19

Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB.


BACKGROUND: The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB.

C. Zeng C. D. Mitnick C. Hewison M. Bastard P. Khan K. J. Seung et al.
J Tuberc Lung Dis. 2023 Jan; 27(1): 34–40. Published online 2023 Jan 1. doi: 10.5588/ijtld.22.0324
tuberculosis drug-resistant tuberculosis rifampin-resistant tuberculosis treatment outcome

Genomic Microevolution of Vibrio cholerae O1, Lake Tanganyika Basin, Africa.


Africa's Lake Tanganyika basin is a cholera hotspot. During 2001-2020, Vibrio cholerae O1 isolates obtained from the Democratic Republic of the Congo side of the lake belonged to 2 of the 5 clades of the AFR10 sublineage.

Hounmanou YMG Njamkepo E Rauzier J Gallandat K Jeandron A Kamwiziku G Porten K Luquero F Abedi AA Rumedeka BB Miwanda B Michael M Okitayemba PW Saidi JM Piarroux R Weill FX Dalsgaard A Quilici ML
Emerging infectious diseases 2023 Jan ; 29(1); . doi: 10.3201/eid2901.220641. Epub 2022 12 28
Africa. Emerg Infect Dis. 2023 Jan [date cited]. African Great Lakes Region Burundi Democratic Republic of Congo Gallandat K Jeandron A Kamwiziku G Lake Tanganyika Lake Tanganyika Basin Njamkepo E Rauzier J Suggested citation for this article: Hounmanou YMG Tanzania Vibrio cholerae Zambia bacteria cholera et al. Genomic microevolution of Vibrio cholerae O1 genomics neglected tropical diseases